The first-and-only 6-month subcutaneous injectable that delivers long-acting HIV prevention.1-4

​
​

The first-and-only 6-month subcutaneous injectable, YEZTUGO delivers long-acting HIV prevention and is recommended by multiple guidelines.1-5

Studied across the broadest range of individuals in 2 PrEP clinical trials1,2,6-8

The PURPOSE 1 and PURPOSE 2 clinical trials, together, represent the most age-, gender-, and racially inclusive, phase 3, PrEP clinical trials to date.

Evaluate the study data

The only twice-yearly
dosing1,2

The first-and-only HIV prevention option that is
2 subcutaneous injections every 6 months, done in office within a ±2-week continuation dosing window from the scheduled injection date.

See dosing details

Multiple ways to acquire YEZTUGO

YEZTUGO offers flexibility so you can choose the acquisition path that best fits your and your patients’ needs. Depending on the payer, YEZTUGO may be covered as either a medical or pharmacy benefit, which will guide how the product is acquired.

Explore options

YEZTUGO: HIV prevention. Widely recognized.1,10-12

Winner in “Best Pharmaceutical Product“ category

Prix Galien USA

One of the “Best Inventions“ in medical and healthcare

TIME Magazine

Lenacapavira selected as “Breakthrough of the Year“

Science Magazine

aLenacapavir for PrEP received FDA approval under the brand name YEZTUGO in 2025.

CDC=Centers for Disease Control and Prevention; FDA=US Food and Drug Administration; IAS-USA=International Antiviral Society-USA; NYSODH AI=New York State Department of Health AIDS Institute; PrEP=pre-exposure prophylaxis; WHO=World Health Organization.

References:
  1. YEZTUGO. Prescribing information. Gilead Sciences, Inc.; 2025.
  2. Full efficacy and safety results for Gilead investigational twice-yearly lenacapavir for HIV prevention presented at AIDS 2024. News release. Gilead Sciences, Inc.; July 24, 2024. Accessed January 6, 2025. https://www.gilead.com/news/news-details/2024/full-efficacy-and-safety-results-for-gilead-investigational-twice-yearly-lenacapavir-for-hiv-prevention-presented-at-aids-2024
  3. Patel RR, Hoover KW, Lale A, Cabrales J, Byrd KM, Kourtis AP. Clinical recommendation for the use of injectable lenacapavir as HIV preexposure prophylaxis—United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74(35):541-549.
  4. Landovitz RJ, Molina JM, Buchbinder SP; International Antiviral Society–USA (IAS–USA) Panel. Preexposure prophylaxis for HIV: updated recommendations from the 2024 International Antiviral Society–USA Panel. JAMA. 2025;334(7):638-639.
  5. World Health Organization. Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-exposure Prophylaxis. World Health Organization; 2025. Accessed October 10, 2025. https://www.who.int/publications/i/item/9789240111608
  6. Bekker LG, Das M, Abdool Karim Q, et al; PURPOSE 1 study team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179-1192.
  7. Kelley CF, Acevedo-Quinones M, Agwu AL, et al; PURPOSE 2 study team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392(13):1261-1276.
  8. Gallardo-Cartagena J, Phanuphak N, Ndlovu N, et al. Global racial, ethnic, and gender diversity among participants enrolled in the PURPOSE 2 trial of lenacapavir for pre-exposure prophylaxis. Paper presented at: 5th HIV Research for Prevention Conference (HIVR4P); October 6–10, 2024; Lima, Peru.
  9. Vail RM, Cantor A, Shah SS, et al. PrEP to prevent HIV and promote sexual health. New York State Department of Health AIDS Institute. Published October 10, 2019. Updated October 16, 2025. Accessed April 7, 2026. https://www.hivguidelines.org/wp-content/uploads/2025/10/NYSDOH-AI-PrEP-to-Prevent-HIV-and-Promote-Sexual-Health_3-25-2026_HG.pdf
  10. Park A. Gilead YEZTUGO. TIME. October 9, 2025. Accessed March 17, 2026. https://time.com/collections/best-inventions-2025/7318444/gilead-yeztugo/
  11. The Galien Foundation honors Michael J. Fox and 2025 Prix Galien Award recipients. News release. The Galien Foundation; October 31, 2025. Accessed March 17, 2026. https://www.prnewswire.com/news-releases/the-galien-foundation-honors-michael-j-fox-and-2025-prix-galien-award-recipients-302600699.html
  12. Cohen J. The long shot. Science. 2024;386(6727):1208-1209.
You are leaving the
YEZTUGO website
Go back Leave site